chuck,
while reading thru the PR's beginning last February, I singled out this paragraph from their Q earnings PR:
"IV Infusion Therapy revenue increased 31% to $7,862,000 for the fourth quarter of 2006 from $5,989,000 in the prior year quarter, the result of continued strong growth in both domestic and international markets. "We were surprised by the strength of our IV Infusion Therapy business in the fourth quarter, and expect revenue growth to return to a more modest pace beginning in the first quarter of 2007," Earhart said."
Is this the unit Hapn will be acquiring if the buy goes through?
I'm not worried about the more modest pace, as Earhart states---IMO, the demographics are still compelling. I also thought, and I might have confused HAPN, with another blank check, HAPN was going to get a NAZ small cap listing.
tia,
lazarre |
